Is there a place for immunotherapy for tumors with oncogenic driver mutations?


Prof. Dr. T. Berghmans, Institut Jules Bordet, Bruxelles
Dr. F. Aboubakar Nana, Cliniques Universitaires St-Luc, Bruxelles
Dr. M. Brandao, Institut Jules Bordet, Bruxelles